Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV

NCT05768854 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.

NCT NCT05768854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV
Lead sponsor
Ultragenyx Pharmaceutical Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 14, 2023
Completion date
April 30, 2027
Enrollment
69 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta